Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.58 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.58 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.58 |
| ▸ | GBA1 | P04062 | 6/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31066865 | 1.00 | GNAI3 (0.58) | GNAI3GNAO1GNAI1GBA1S1PR4 | |
| SCHEMBL24803090 | 1.00 | GNAI3 (0.58) | GNAI3GNAO1GNAI1GBA1S1PR4 | |
| SCHEMBL21949297 | 1.00 | GNAI3 (0.58) | GNAI3GNAO1GNAI1GBA1S1PR4 | |
| SCHEMBL31066862 | 1.00 | GNAI3 (0.58) | GNAI3GNAO1GNAI1GBA1S1PR4 | |
| SCHEMBL31066880 | 1.00 | GNAI3 (0.58) | GNAI3GNAO1GNAI1GBA1S1PR4 | |
| SCHEMBL25448549 | 0.98 | GNAI3 (0.55) | GNAI3GNAO1GNAI1GBA1S1PR4 | |
| SCHEMBL13301319 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1S1PR4S1PR1 | |
| SCHEMBL24072425 | 0.89 | GNAI3 (0.50) | GNAI3GNAO1GNAI1GBA1S1PR4 | |
| SCHEMBL4623536 | 0.84 | MEN1 (0.43) | GNAI3GNAO1GNAI1 | |
| SCHEMBL24210534 | 0.83 | GNAI3 (0.70) | GNAI3GNAO1GNAI1GBA1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | GNAI3 2001/4885GNAO1 3832/4885GNAI1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.